靶向微粒体前列腺素 E2 合酶-1 的抗炎药物研究进展

Shuang Ji; Lihong Chen

doi:10.11665/j.issn.1000-5048.2023032001

靶向微粒体前列腺素 E₂ 合酶-1 的抗炎药物研究进展

Translated title of the contribution: Research advances in microsomal prostaglandin E₂ synthase-1 targeted anti-inflammatory drugs

Shuang Ji
, Lihong Chen^*

^*Corresponding author for this work

Dalian Medical University

Research output: Contribution to journal › Review article › peer-review

Abstract

Microsomal prostaglandin E₂ synthase 1 (mPGES-1), the main terminal synthase of prostaglandin E₂ (PGE₂), plays a crucial role in inflammatory diseases. Compared to non-steroidal anti-inflammatory drugs (NSAIDs), mPGES-1 inhibitors are promising agents for their better specificity and higher safety. This article summarizes the research status of mPGES-1 in inflammation and cardiovascular diseases, systematically reviews the research progress of the development of mPGES-1 inhibitors, elaborates on their therapeutic effects in different inflammation animal models and inflammatory diseases, and discusses the possible existing challenges, aiming to provide some guidance and reference for the subsequent research of anti-inflammatory drugs.

Translated title of the contribution	Research advances in microsomal prostaglandin E₂ synthase-1 targeted anti-inflammatory drugs
Original language	Chinese (Traditional)
Pages (from-to)	697-707
Number of pages	11
Journal	Journal of China Pharmaceutical University
Volume	55
Issue number	5
DOIs	https://doi.org/10.11665/j.issn.1000-5048.2023032001
State	Published - Oct 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11665/j.issn.1000-5048.2023032001

Cite this

@article{51139877bb3945119efb9314b82c27ce,

title = "靶向微粒体前列腺素 E2 合酶-1 的抗炎药物研究进展",

abstract = "Microsomal prostaglandin E2 synthase 1 (mPGES-1), the main terminal synthase of prostaglandin E2 (PGE2), plays a crucial role in inflammatory diseases. Compared to non-steroidal anti-inflammatory drugs (NSAIDs), mPGES-1 inhibitors are promising agents for their better specificity and higher safety. This article summarizes the research status of mPGES-1 in inflammation and cardiovascular diseases, systematically reviews the research progress of the development of mPGES-1 inhibitors, elaborates on their therapeutic effects in different inflammation animal models and inflammatory diseases, and discusses the possible existing challenges, aiming to provide some guidance and reference for the subsequent research of anti-inflammatory drugs.",

keywords = "inflammatory diseases, mPGES-1, non-steroidal anti-inflammatory drugs, prostaglandin E",

author = "Shuang Ji and Lihong Chen",

year = "2024",

month = oct,

doi = "10.11665/j.issn.1000-5048.2023032001",

language = "繁体中文",

volume = "55",

pages = "697--707",

journal = "Journal of China Pharmaceutical University",

issn = "1000-5048",

publisher = "China Pharmaceutical University",

number = "5",

}

TY - JOUR

T1 - 靶向微粒体前列腺素 E2 合酶-1 的抗炎药物研究进展

AU - Ji, Shuang

AU - Chen, Lihong

PY - 2024/10

Y1 - 2024/10

N2 - Microsomal prostaglandin E2 synthase 1 (mPGES-1), the main terminal synthase of prostaglandin E2 (PGE2), plays a crucial role in inflammatory diseases. Compared to non-steroidal anti-inflammatory drugs (NSAIDs), mPGES-1 inhibitors are promising agents for their better specificity and higher safety. This article summarizes the research status of mPGES-1 in inflammation and cardiovascular diseases, systematically reviews the research progress of the development of mPGES-1 inhibitors, elaborates on their therapeutic effects in different inflammation animal models and inflammatory diseases, and discusses the possible existing challenges, aiming to provide some guidance and reference for the subsequent research of anti-inflammatory drugs.

AB - Microsomal prostaglandin E2 synthase 1 (mPGES-1), the main terminal synthase of prostaglandin E2 (PGE2), plays a crucial role in inflammatory diseases. Compared to non-steroidal anti-inflammatory drugs (NSAIDs), mPGES-1 inhibitors are promising agents for their better specificity and higher safety. This article summarizes the research status of mPGES-1 in inflammation and cardiovascular diseases, systematically reviews the research progress of the development of mPGES-1 inhibitors, elaborates on their therapeutic effects in different inflammation animal models and inflammatory diseases, and discusses the possible existing challenges, aiming to provide some guidance and reference for the subsequent research of anti-inflammatory drugs.

KW - inflammatory diseases

KW - mPGES-1

KW - non-steroidal anti-inflammatory drugs

KW - prostaglandin E

UR - https://www.scopus.com/pages/publications/105000754554

U2 - 10.11665/j.issn.1000-5048.2023032001

DO - 10.11665/j.issn.1000-5048.2023032001

M3 - 文献综述

AN - SCOPUS:105000754554

SN - 1000-5048

VL - 55

SP - 697

EP - 707

JO - Journal of China Pharmaceutical University

JF - Journal of China Pharmaceutical University

IS - 5

ER -

靶向微粒体前列腺素 E₂ 合酶-1 的抗炎药物研究进展

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this